Philips Accelerates the Development of Magnetic Particle Imaging Technology

PhilipsRoyal Philips Electronics (NYSE: PHG, AEX: PHI) has initiated a German public-private partnership that aims to advance the development of whole-body Magnetic Particle Imaging (MPI) systems and preclinical hybrid systems that combine MPI with Magnetic Resonance Imaging (MRI). The German Federal Ministry of Education and Research has made a commitment to provide EUR 10.6 million funding to the consortium partners. The target size of the consortium budget, comprising contributions from the German government and the consortium's public/private partners, is EUR 20.3 million.

Philips is committed to delivering leading-edge imaging solutions to help in the early detection, diagnosis and treatment of disease. Researching future-generation imaging technologies such as MPI underpins the long-term nature of this commitment. MPI was invented by scientists at Philips. It relies on the magnetic properties of iron-oxide nanoparticles (the so-called tracer) that are injected into the bloodstream. An MPI system spatially and quantitatively detects these iron-oxide nanoparticles in order to produce three-dimensional images of physiological processes. The technology has already proved capable of capturing accurate real-time 3D-images of blood flow and heart motion in mice.

"As part of our Open Innovation approach, Philips has initiated the Magnetic Particle Imaging Technology - MAPIT - consortium to accelerate the translation of this innovative new imaging concept into clinical practice," says Michael Kuhn, Vice President Technology Strategy at Philips Healthcare. "Realizing the full potential of MPI to help in elucidating the processes associated with disease requires an integrated approach and a collaborative effort. I am convinced that the multidisciplinary MAPIT consortium is well positioned to advance MPI development in the areas of instrumentation, tracers, and application research."

"Constant improvements in medical imaging technology have significantly boosted advances in healthcare. Based on the level of performance that has been demonstrated in preclinical studies, I consider MPI to be a new imaging modality with the real potential to improve diagnostic imaging in cardiology and oncology, as well as being a tremendous tool for the advancement of molecular imaging in general," says Professor Bernd Hamm, Director of the Department of Radiology and Chair of Radiology at the Charité - Universitätsmedizin Berlin.

Philips and the University of Lübeck, two of the three proposed consortium partners in the instrumentation area, will focus on the development of whole-body MPI demonstrators. The third instrumentation partner, Bruker Corporation (NASDAQ: BRKR), will focus on developing a simultaneous or consecutive preclinical MPI plus MRI capability. This will complement the functional MPI information with morphological information from MRI for the purposes of preclinical imaging. In the area of tracer development, the proposed partners Bayer Schering Pharma AG, Miltenyi Biotec, Charité-Universitätsmedizin Berlin and the Physikalisch-Technische Bundesanstalt (PTB) aim to develop magnetic nanoparticle materials optimized for MPI.

Two principal application areas will be explored by the consortium: functional cardiovascular measurements (such as myocardial perfusion) and image-guidance of cardiovascular interventions (using interventional devices optimized for MPI guidance).

The results achieved at the Philips Research Laboratories in Hamburg (Germany) in the preceding MAGIC (Magnetic Particle Imaging for Cardiovascular Applications) research consortium contributed significantly to the development of MPI. The MAGIC project, which was also funded by the German Federal Ministry of Education and Research, has already resulted in an agreement between Philips and Bruker Biospin regarding the commercialization of MPI scanners for the preclinical market.

Related news articles:

About Royal Philips Electronics
Royal Philips Electronics of the Netherlands (NYSE: PHG, AEX: PHI) is a diversified health and well-being company, focused on improving people’s lives through timely innovations. As a world leader in healthcare, lifestyle and lighting, Philips integrates technologies and design into people-centric solutions, based on fundamental customer insights and the brand promise of "sense and simplicity". Headquartered in the Netherlands, Philips employs more than 118,000 employees in more than 60 countries worldwide. With sales of US 32.3 billion in 2009, the company is a market leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as lifestyle products for personal well-being and pleasure with strong leadership positions in flat TV, male shaving and grooming, portable entertainment and oral healthcare.

Most Popular Now

Using Data and AI to Create Better Healt…

Academic medical centers could transform patient care by adopting principles from learning health systems principles, according to researchers from Weill Cornell Medicine and the University of California, San Diego. In...

AI Medical Receptionist Modernizing Doct…

A virtual medical receptionist named "Cassie," developed through research at Texas A&M University, is transforming the way patients interact with health care providers. Cassie is a digital-human assistant created by Humanate...

Northern Ireland Completes Nationwide Ro…

Go-lives at Western and Southern health and social care trusts mean every pathology service is using the same laboratory information management system; improving efficiency and quality. An ambitious technology project to...

AI Tool Set to Transform Characterisatio…

A multinational team of researchers, co-led by the Garvan Institute of Medical Research, has developed and tested a new AI tool to better characterise the diversity of individual cells within...

Human-AI Collectives Make the Most Accur…

Diagnostic errors are among the most serious problems in everyday medical practice. AI systems - especially large language models (LLMs) like ChatGPT-4, Gemini, or Claude 3 - offer new ways...

AI Detects Hidden Heart Disease Using Ex…

Mass General Brigham researchers have developed a new AI tool in collaboration with the United States Department of Veterans Affairs (VA) to probe through previously collected CT scans and identify...

Highland Marketing Announced as Official…

Highland Marketing has been named, for the second year running, the official communications partner for HETT Show 2025, the UK's leading digital health conference and exhibition. Taking place 7-8 October...

MHP-Net: A Revolutionary AI Model for Ac…

Liver cancer is the sixth most common cancer globally and a leading cause of cancer-related deaths. Accurate segmentation of liver tumors is a crucial step for the management of the...

AI Detects Early Signs of Osteoporosis f…

Investigators have developed an artificial intelligence-assisted diagnostic system that can estimate bone mineral density in both the lumbar spine and the femur of the upper leg, based on X-ray images...

Forging a Novel Therapeutic Path for Pat…

Rett syndrome is a devastating rare genetic childhood disorder primarily affecting girls. Merely 1 out of 10,000 girls are born with it and much fewer boys. It is caused by...

AI could Help Pathologists Match Cancer …

A new study by researchers at the Icahn School of Medicine at Mount Sinai, Memorial Sloan Kettering Cancer Center, and collaborators, suggests that artificial intelligence (AI) could significantly improve how...

Integrating Care Records is Good. Using …

Opinion Article by Dr Paul Deffley, Chief Medical Officer, Alcidion. A single patient record already exists in the NHS. Or at least, that’s a perception shared by many. A survey of...